Showing 1 - 10 of 1,746
Using a reduced form binary econometric model, we analyze the determinants of pharmaceutical companies entry decisions into new submarkets. Our sample includes data for pharmaceutical companies over the period 1987-1998 for seven countries. Estimation is done both at the aggregate level and at a...
Persistent link: https://www.econbiz.de/10012708979
Persistent link: https://www.econbiz.de/10003463005
An explosion of knowledge and a growing array of tools and technologies have transformed modern drug Ramp;D, while its cost has risen by a sizable amount. At the same time, the unchecked increase in health care and prescription drug spending has spawned cost containment policies that are...
Persistent link: https://www.econbiz.de/10012751737
availability of health-related products such as pharmaceuticals, vaccines, and medical equipment. The case for liberalizing trade …
Persistent link: https://www.econbiz.de/10011591118
Access to medicines at prices patients can afford has been a recurrent concern for the global community ever since the Agreement on Trade Related Aspects of Intellectual Property (TRIPS) was adopted in 1995 as one of the agreements under the World Trade Organization (WTO). In 2001, WTO Members...
Persistent link: https://www.econbiz.de/10012316008
market structure and market size, focusing on the competitive roles of the endogenous sunk costs of advertising and …Jüngere Entwicklungen der Literatur zum Thema "Marktstruktur" ermöglichen es, robuste testbare Hypothesen aus der … versunkener Kosten für Werbung und/oder Forschung und Entwicklung (FuE) auf den Wettbewerb untersucht. Die empirischen Ergebnisse …
Persistent link: https://www.econbiz.de/10010514955
Persistent link: https://www.econbiz.de/10001378739
Persistent link: https://www.econbiz.de/10013287631
Persistent link: https://www.econbiz.de/10012109480
Persistent link: https://www.econbiz.de/10003808362